CD38 and Miyoshi myopathy: At present, isatuximab is the only anti‐CD38 mAb that could induce direct apoptosis in MM cells, although only in patients with elevated CD38 expression, whereas daratumumab may induce apoptosis, but only in the presence of cross‐linking agents.13, 51, 52, 53, 54, 55